The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Breast cancer–specific mortality in invasive lobular versus ductal carcinoma over 30 years.
 
Jose Leone
Consulting or Advisory Role - Minerva Biotechnologies
Research Funding - Kazia Therapeutics (Inst); Lilly (Inst); Roche/Genentech (Inst)
 
Julieta Leone
No Relationships to Disclose
 
Noah Graham
No Relationships to Disclose
 
Julian Iturbe
No Relationships to Disclose
 
Kristina Fanucci
No Relationships to Disclose
 
Rinath Jeselsohn
Consulting or Advisory Role - AstraZeneca; Carrick Therapeutics; Lilly; Novartis; Pfizer
Research Funding - Lilly; Novartis; Pfizer; Recursion Pharmaceuticals (Inst)
 
Guilherme Nader Marta
Travel, Accommodations, Expenses - AstraZeneca
 
Carlos Vallejo
No Relationships to Disclose
 
Nancy Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Daiichi Sankyo; Eisai; Menarini; Olema Pharmaceuticals; Pfizer; Seagen; Shorla Oncology
Research Funding - AstraZeneca (Inst); Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Olema Pharmaceuticals
 
Sara Tolaney
Consulting or Advisory Role - AADi; Aktis Oncology; Ambrx; Arvinas; AstraZeneca; Avenzo Therapeutics; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Boehringer Ingelheim; Boundless Bio; Bristol-Myers Squibb; Celcuity; Circle Pharma; Corcept Therapeutics; Cullinan Oncology; Daiichi Sankyo; Denali Therapeutics; eFFECTOR Therapeutics; Eisai; Ellipses Pharma; Genentech; Immunomedics/Gilead; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Novartis; Olema Pharmaceuticals; Pfizer; Reveal Genomics; Samsung Bioepis; Seagen; Summit Therapeutics; Systimmune; Tempus; Zuellig Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; AstraZeneca; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Meredith Regan
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Tersera; Tolmar
Research Funding - Bayer (Inst); bioTheranostics (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Nabihah Tayob
No Relationships to Disclose
 
Otto Metzger
Honoraria - AstraZeneca; Merck
Consulting or Advisory Role - Grupo Oncoclinicas
Research Funding - Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Grupo Oncoclinicas